Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
Ulster University2mon
Targeting glucagon-like peptides for the treatment of diabetes and obesity
Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted from the same intestinal cells following meal ingestion. GLP-1 is now widely recognised to reduce blood glucose levels ...
HealthDay on MSN2d
Age Differences Seen in Efficacy of Type 2 Diabetes Treatments
Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in ...
standardmedia.co.ke6mon
A full analysis of Retatrutide and Tirzepatide Peptides
Studies suggest that the peptide may activate receptors involved in energy balance, such as the glucagon-like peptide-1 (GLP-1) receptor, glucagon receptor (GCGR), and glucose-dependent ...